Press Releases – NASDAQ (US) Website

Press Releases

Aug 10, 2017
BeiGene Announces Pricing of $175 Million Public Offering    read more...
Aug 09, 2017
BeiGene Announces Proposed Public Offering    read more...
Aug 09, 2017
BeiGene Reports Second Quarter 2017 Financial Results    read more...
Jul 05, 2017
BeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene    read more...
Jul 05, 2017
BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer    read more...
Jun 29, 2017
BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer    read more...
Jun 16, 2017
BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111    read more...
Jun 15, 2017
BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 14th International Conference on Malignant Lymphoma    read more...
Jun 14, 2017
BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma    read more...
Jun 07, 2017
BeiGene to Present at Upcoming Investor Conferences    read more...
Jun 07, 2017
BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call    read more...
Jun 05, 2017
BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting    read more...
May 17, 2017
BeiGene to Present at the 2017 UBS Global Healthcare Conference    read more...
May 10, 2017
BeiGene Reports First Quarter 2017 Financial Results    read more...
Apr 21, 2017
BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317    read more...
Apr 21, 2017
BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting    read more...
Apr 02, 2017
BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting    read more...
Mar 22, 2017
BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results    read more...
Mar 09, 2017
BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL    read more...
Mar 07, 2017
BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility    read more...